Total Funding
86
77
Total FundingPost-IPO Equity raised
Growth Score
-1 pts
Heat Score
11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
94286
TiumBio is a drug developer working on treatments for cancer.
Kim Hun-taek: Founder & CEO
About the Company
TiumBio is an R&D company that creates innovative new drugs. The company provides services for cancer, hemophilia, type 2 diabetes, and idiopathic pulmonary fibrosis. TiumBio develops NCE401, NCE403, NBP604, and NBP611. NCE401 is a substance for the treatment of fibrosis while NCE403 is for treating endomitriosis, NBP604 is for hemophilia and
works a neutralizing antibody, and lastly NBP611, for the treatment of hemophilia B.
